Overview
Public BiotechPhase 2DMT
Developing GH001 (5-MeO-DMT) for treatment-resistant depression via inhalation.
Visit WebsiteDublin, Ireland
$180M
Market Cap
2018
Founded
40
Employees
0
Open Roles
Open Positions
No open positions at this time
Research Areas
Clinical Pipeline(8)
Completed·Phase 1·DMT
Safety and Pharmacokinetics of GH002 in Healthy Volunteers
5 Methoxy N,N DimethyltryptamineHealthy Volunteers
Completed·Phase 1·DMT
Pharmacokinetics of GH001 in Healthy Volunteers
5 Methoxy N,N DimethyltryptamineHealthy Volunteers
Terminated·Phase 2·DMT
Phase 2 Clinical Trial of GH001 in Postpartum Depression
GH001Postpartum Depression
Recruiting·Phase 1·DMT
Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
5 Methoxy N,N DimethyltryptamineHealthy Volunteers
Completed·Phase 2·DMT
A Trial of GH001 in Patients With Treatment-resistant Depression
GH001Treatment-resistant Depression
Completed·Phase 1·DMT
Clinical Study of GH001 in Depression
5 Methoxy N,N DimethyltryptamineTreatment Resistant Depression
Terminated·Phase 2·DMT
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
GH001Bipolar II Disorder
Completed·Phase 1·DMT
Safety of GH001 in Healthy Volunteers
5 Methoxy N,N DimethyltryptamineHealthy Volunteers